{"groups":[{"description":"Busulfan 32 mg/m\\^2 intravenous (IV) for 1 Day then 130 mg/m\\^2 IV for 4 Days; and Melphalan 70 mg/m\\^2 IV for 2 Days","id":"FG000","title":"Busulfan + Melphalan"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"164"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"164"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Among the participants enrolled, two were excluded from the trial before starting any treatment. There are two participants who were enrolled on the study twice (having to temporarily leave then re-enter the study).","recruitmentDetails":"Recruitment Period: 2/4/2005 through 10/29/2010. All participant recruitment attempted at UT MD Anderson Cancer Center."}